May 2025 in “The Journal of Rheumatology” Atypical symptoms in lupus can indicate different kidney issues.
May 2025 in “The Journal of Rheumatology” Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
May 2025 in “The Journal of Rheumatology” Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
The document tests knowledge and decision-making in hematology through multiple-choice questions.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
12 citations
,
May 2020 in “Dermatology and therapy” A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
1 citations
,
October 2025 in “Journal of Dermatological Treatment” Dupilumab improves eczema in Netherton Syndrome but not ichthyosis linearis circumflexa.
2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” Ocrelizumab may cause total body hair loss in some patients.
610 citations
,
April 2014 in “Nature Reviews Immunology” The document concludes that understanding how the skin's immune system and inflammation work is complex and requires more research to improve treatments for skin diseases.
405 citations
,
May 2007 in “Journal of The American Academy of Dermatology” Obesity affects skin health, causing conditions like acanthosis nigricans and may require different treatment approaches.
205 citations
,
April 2013 in “British Journal of Dermatology” Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.